NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Skye Peptides

Published 12 Nov 2026. 31-page investigative report on who is behind Skye Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 93 Finnrick lab tests, Skye Peptides posts a 52% overall pass rate (48 pass / 45 fail). The result is uneven rather than uniformly bad: semaglutide and tirzepatide are the strongest mature lanes, while BPC-157 and CJC-1295 are the clearest weak points. The report’s methodology-sensitivity work shows why product-level review matters here.

Beyond the lab record, the investigation finds a real but opaque operating structure. Skye Research, LLC is an active Wyoming entity tied to the official storefront, while a separate Wyoming IP holder controls the Skye-family trademarks and licenses the mark back to the operator. A UDRP record refers to an unnamed Skye Research CTO, but the public sources reviewed do not identify the QA or batch-release decision maker.

Operational transparency tightened in 2026. The storefront was fully login-gated by late July; the terms later shifted to a 21+ membership model, removed older public refund language, and put the COA library behind registration. Skye has Janoshik and Accumark/Valence documentation, but several GLP-1 product-page batch banners did not align with the reviewed COA index, making vial-level verification essential.

Skye also has an active impersonation problem. UDRP records credit the company with repeated brand-enforcement wins, yet two Skye-branded clones remained live when reviewed, one after a transfer order. No FDA warning letter, FTC action, or public court case naming Skye was found in this pass; the buyer-specific concerns are product dispersion, accountability, documentation matching, and channel verification.

Inside the full report:

  • Per-product Finnrick pass/fail rates, rating trajectories, and methodology-divergence charts for all 12 products
  • Corporate and trademark trail linking Skye Research, SG IP Holdings, Skye Health and Skyetides, with unresolved ownership marked
  • Policy diff of the September and October 2026 terms, including membership, age, refund and BAC-water changes
  • COA-chain analysis from product-page batch banners to Janoshik and Accumark/Valence verification records
  • Clone-domain timeline with UDRP decisions, live status, and buyer-verification guidance

Risk assessment

  • Product-specific quality risk — BPC-157, CJC-1295, Tesamorelin, TB-500, Melanotan II, Survodutide — high: Finnrick shows BPC-157 at 5 pass / 12 fail across 17 tests, CJC-1295 at 2 / 5 across 7, Tesamorelin at 2 / 6 across 8, TB-500 at 1 / 2 across 3, and zero passes for Melanotan II and Survodutide; semaglutide, tirzepatide, retatrutide and small-sample GHK-Cu test materially better.
  • Corporate accountability and UBO opacity — high: Skye Research, LLC is a Wyoming nominee-address LLC with two officers not publicly named in the reviewed records, while SG IP Holdings LLC and Skye Research Investments LLC add affiliate layers; no natural-person owner was established.
  • Copycat and brand-confusion risk — high: Sixteen UDRP proceedings are reported, yet skyepeptides-us.com and blueskyepeptides.com were still live clones on 2026-11-11 and the gated official site exposed no public authorized-channel list.
  • Batch-documentation mismatch on GLP-1 products — medium: GLP-1 R, GLP-1 T and GLP-1 S product-page batch codes did not appear in Skye's 44-record COA index, while newer Accumark-tested lots did; buyers must verify the vial code in the lab portal.
  • Payment and delivery complaints — medium: Trustpilot fell to 3.8/5 from 50 reviews, with 2026 complaints describing irreversible payment, surprise shipper fees, non-delivery and non-response; clone-site fraud may explain some reports but the buyer exposure is real.
  • Manufacturing-origin verification concern — medium: The site navigation asserted USA Made, but no manufacturing facility record, FDA registration, import record or third-party manufacturing audit was found; COAs verify submitted samples, not origin.
  • Undisclosed affiliate-promotion risk — medium: The available promotion scan found multiple code/deal promoters with no clear disclosure, including an X code promoter and coupon/SEO pages; evidence does not prove Skye controlled every listing.